SecBot SecBot

XBIT

XBiotech Inc.
Nasdaq· Pharmaceutical Preparations· Inc. A1· CIK 0001626878 Biotech & Drug Discovery
$1.85 −0.08 (−4.15%)
Oct 26 4:00 PM ET · prev $1.93
Market cap
$60.1M
Micro cap
Next earnings
Nov 10
in 14 days
1 year
−28.0%
from $2.57 · Oct 27
30 days
−14.0%
from $2.15
52-week range
$1.85–2.94
at the low
Avg volume 20D
72.3K
Oct 19 spike 384.4K
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
3
analyzed by SecBot
SecBot read BEARISH 2 reports · 90 days
Balance 1 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 10, 2026
Strongest BEARISH XBiotech's 2026 definitive proxy statement schedules a virtual annual meeting for November 24, 2026, with…
All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 2 trimmed or exited.

  • TrendDOWNTREND

    15% below its 50-day average. New closing low $1.85 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
RENAISSANCE TECHNOLOGIES LLCADD41,663$95.8K
Qube Research & Technologies LtdADD33,570$77.2K
BANK OF AMERICA CORP /DE/TRIM23,789$54.7K
JANE STREET GROUP, LLCNEAR_EXIT11,476$26.4K
Squarepoint Ops LLCTRIM41,214$96.9K
DIMENSIONAL FUND ADVISORS LPTRIM36,053$84.5K
JPMORGAN CHASE & CONEAR_EXIT96$218.00
CWM, LLCTRIM13$31.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Apr 2020
Recent actions
DateFirmActionRating
Apr 7, 2020Piper Sandler
MAINTAIN
MAINTAINOverweight
Dec 11, 2019Piper Sandler
MAINTAIN
MAINTAINOverweight
Jun 14, 2019Piper Sandler
INITIATE
INITIATEOverweight

Earnings setup

Estimates
Nov 10
reports in 14 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
XBIT Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Aug 11, 2026
Earnings date
XBIT Q2 2026 Earnings Scheduled — 2026-08-11
Aug 4, 2026
Clinical Trial
XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer
Phase 2 · COMPLETED
Jun 15, 2026
Press release
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis
IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment
May 12, 2026
Earnings date
XBIT Q1 2026 Earnings Scheduled — 2026-05-12
Mar 16, 2026
Earnings date
XBIT Q4 2025 Earnings Scheduled — 2026-03-16

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 2, 2026 SEC
XBiotech's 2026 definitive proxy statement schedules a virtual annual meeting for November 24, 2026, with three…
DEF 14A — Impact 5/10
Aug 11, 2026 Earnings calendar
XBIT Q2 2026 Earnings Scheduled — 2026-08-11
Jun 30, 2026 Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
41,663 shares ($95.8K)
Jun 30, 2026 Inst.
Qube Research & Technologies — ADD
33,570 shares ($77.2K)
Apr 29, 2026 SEC
XBiotech filed Amendment No. 1 to its 2025 10-K solely to include Part III information (directors, executive…
10-K/A — Impact 2/10

SecBot reports

3 filings · 0 bullish · 1 bearish · 2 neutral
All XBIT filing & press-release reports (3)